Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Citi bullish on 'streamlined' Johnson & Johnson after Kenvue IPO

Published 05/30/2023, 09:42 PM
Updated 05/30/2023, 09:42 PM
© Reuters.

© Reuters.

Citi analysts resumed the research coverage of Johnson & Johnson (NYSE:JNJ) with a Buy rating and a $185 per share.

JNJ’s healthcare business Kenvue made its trading debut earlier in May after the former sold 172.8 million shares at $22 apiece.

"What remains is world-leading medical technology and pharmaceutical franchises, which can focus R&D (and management energy) on respective pipelines while creating a more cohesive drug/device potential," the analysts said in the client note.

They see several positive catalysts that could help shares to re-rate higher, including recovering patient volumes, a robust new product pipeline, talc litigation settlement progress, as well as the completion of the strategic transformation.

"In other words, there is momentum at the new, streamlined JNJ," the analysts said.

The price target offers a 20% upside potential.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.